Slide 1: Myriad Genetics Fiscal Fourth-Quarter 2016 Earnings Call
Myriad Genetics Fiscal Fourth-Quarter 2016 Earnings Call 08/09/2016 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or res
Slide 3: Fiscal Year 2016 Financial Results
Fiscal Year 2016 Financial Results FY16 Actual Results YoY Growth Revenue $753.8M 4% Adjusted EPS $1.63 12% GAAP EPS $1.71 58%
Slide 4: Hereditary Cancer Revenue Remains Relatively Stable
Hereditary Cancer Revenue Remains Relatively Stable Hereditary Cancer Revenue ($ in mil.)
Slide 5: Substantial Progress With Key Pipeline Products
Substantial Progress With Key Pipeline Products Test Volume YoY Volume Growth New Private Payer Lives 15,300 94% 29M 160,000 11% 3M
Slide 6: Extensive Collaborations With >22 PARP Clinical Studies
Extensive Collaborations With >22 PARP Clinical Studies NSCLC (240,000) Global Market > 1.4M patients or $6.0B* Neoadjuvant BC (143,000) Ovarian (60,000) FY15 FY16 FY17 FY18 FY19 FY20 *Includes U.S., Canada and EU6 Pancreatic (102,000) Metastatic Prostate (80,000) Colon (278,000) Gastric (114,000) H
Slide 7: Advancing Key Tests Toward Market Adoption
Advancing Key Tests Toward Market Adoption Total Addressable Market (TAM) $10B+ $10B+ $15B $5B Product Stage 1 DISCOVERY Stage 2 VALIDATION Stage 3 REIMBURSEMENT Stage 4 ADOPTION myRisk® Hereditary Cancer BRACAnalysis CDx™ (Tumor) EndoPredict® myChoice™ HRD myPlan® Lung Cancer myRisk® Hereditary Can
Slide 8: Two Acquisitions Additive To Five Year Plan
Two Acquisitions Additive To Five Year Plan Global leader in genetic testing for drug selection in mental health market Core product is GeneSight®, which provides individualized treatment recommendations on 55 antidepressant, antipsychotic, and other mental health medications Currently call primaril
Slide 9: Fiscal Fourth-Quarter 2016 Revenue By Product
Fiscal Fourth-Quarter 2016 Revenue By Product Product 4Q16 4Q15 YoY Growth Hereditary Cancer $152.8 $163.8 (7%) Vectra DA $12.7 $11.8 8% Prolaris $3.5 $0.7 400% Other $4.8 $2.5 92% Total Molecular Diagnostic Revenue $173.8 $178.8 (3%) Pharmaceutical & Clinical Services $12.7 $11.1 14% Total Revenue
Slide 10: Fiscal Fourth-Quarter Financial Results
Fiscal Fourth-Quarter Financial Results 4Q16 4Q15 YoY Growth Total Revenue $186.5 $189.9 (2%) Gross Profit $146.5 $152.4 (4%) Gross Margin 78.6% 80.3% NA Operating Income $35.7 $36.2 (1%) Adjusted Operating Income $39.0 $48.2 (19%) Adjusted Operating Margin 20.9% 25.4% NA Net Income $23.4 $18.7 25%
Slide 11: 1Q17 and FY17 Financial Guidance
1Q17 and FY17 Financial Guidance Metric Fiscal First-Quarter 2017 Fiscal Year 2017 Revenue $168 to $170 million $740 to $760 million Diluted EPS $0.14 to $0.16 $0.47 to $0.57 Adjusted EPS $0.25 to $0.27 $1.00 to $1.10 For additional information on GAAP to non-GAAP reconciliation see: https://www.myr
Slide 12: Hereditary Cancer Has Been Stable for Last Quarters
Hereditary Cancer Has Been Stable for Last 10 Quarters Hereditary Cancer Revenue (in mil.) Impact from celebrity publicity
Slide 13: Guidance Assumptions for FY17
Guidance Assumptions for FY17 Potential Downsides Hereditary cancer out of network decisions Base Case Hereditary cancer decrease consistent with Q4 FY16 YoY decline No incremental payer coverage for Vectra DA, GeneSight, Prolaris or EndoPredict No revenue from myPath, myPlan Lung Cancer or myChoice
Slide 14: Market Expansion Opportunity in Hereditary Cancer Exceeds $1B Annually
Market Expansion Opportunity in Hereditary Cancer Exceeds $1B Annually Indication Added Market Potential Guidelines Contracting Colon Cancer @ 5% Mutation Risk +$100M 53% All Endometrial Cancer +$150M 53% Breast Cancer <60 years +$150M FY17 FY18 All Pancreatic Cancer +$125M Partial FY17 Prostate Can
Slide 15: Two Improvements to myRisk Hereditary Cancer Test
Two Improvements to myRisk Hereditary Cancer Test Gene additions added to NCCN Guidelines in June 2016 GREMM1 POLE POLD1 25 Current myRisk genes NBN 1. Updating gene content to provide better care 2. Offering customizable format for customers
Slide 16: PROMPT Study Shows Discordance Between Hereditary Cancer Laboratories
PROMPT Study Show Discordance Between Hereditary Cancer Laboratories n=603 n=155 26% n=98 64% n=57 36% Conflicting interpretation between laboratories Non-clinically significant Altered surveillance recommendation Source: PROMPT Study presented at ASCO 2016 Annual Meeting ≈ 1 in 10 patients would ha
Slide 17: New Product Pipeline Market Opportunity
New Product Pipeline Market Opportunity Currently Reimbursed Market Opportunity Total Market Opportunity (in billions) > $1B Reimbursed TAM
Slide 18: Three New Commercial Contracts for Vectra DA and Prolaris
Three New Commercial Contracts for Vectra DA and Prolaris Medicare Commercial Insurers 1.5 million RA patients 200,000 localized prostate cancer patients Commercial Insurers Medicare Favorable Int.
Slide 19: EndoPredict Most Often Correct When Test Result Disagrees With Oncotype Dx
EndoPredict Most Often Correct When Test Result Disagrees With Oncotype Dx *Data presented at San Antonio Breast Cancer Symposium in 2015 from the TransATAC cohort Oncotype Dx is a registered trademark of Genomic Health Inc. Non-Low 10.2% 29.9% Low 4.6% 26.9% Low High Rate of 10-year Distant Metasta
Slide 20: GeneSight Is One of the Fastest Growing New Diagnostic Tests in History
GeneSight Is One of the Fastest Growing New Diagnostic Tests in History Less than 5% market penetration to date GeneSight (MYGN) Oncotype Dx is a registered trademark of Genomic Health Inc., FoundationOne is a trademark of Foundation Medicine Inc., Afirma is a trademark of Veracyte Inc.
Slide 21: Most Major Depressive Disorder Patients are Seen in Primary Care
Most Major Depressive Disorder Patients are Seen in Primary Care Treating Physician for Patients With MDD Significant shortage of psychiatrists in U.S. and getting worse Most MDD patients are seen by primary care consisting of general practice, internal medicine, and OBGYNs Top 16,000 primary care p
Slide 22: Niraparib Highly Efficacious in Both myChoice HRD+ and Germline BRCA+ Patients
Niraparib Highly Efficacious in Both myChoice HRD+ Patients and Germline BRCA+ Patients p<0.0001 ? 21.0 Progression Free Survival (Months) p<0.0001
Slide 23: Extensive Collaborations With >22 PARP Clinical Studies
Extensive Collaborations With >22 PARP Clinical Studies NSCLC (240,000) Global Market > 1.4M patients or $6.0B* Neoadjuvant BC (143,000) Ovarian (60,000) FY15 FY16 FY17 FY18 FY19 FY20 *Includes U.S., Canada and EU6 Pancreatic (102,000) Metastatic Prostate (80,000) Colon (278,000) Gastric (114,000) H
Slide 24: Completing myPath Melanoma Reimbursement Dossier
Completing myPath Melanoma Reimbursement Dossier myPath Melanoma Diagnostic Accuracy myPath Melanoma Diagnostic Accuracy myPath Melanoma Clinical Utility n=437 patients n=736 patients n=218 patients Favorable outcomes study to be presented
Slide 25: Building Towards >$600M Global Market for EndoPredict
Building Towards >$600M Global Market for EndoPredict $31M $9M $52M $54M $50M $66M $305M FY20 Market Penetration Revenue 5% $33M 10% $66M 25% $165M Currently at about 10% market penetration in Germany and Switzerland $100M
Slide 26: Incremental Revenue With Broad Reimbursement
Incremental Revenue With Broad Reimbursement Revenue (in millions) Fully reimbursed at FY16 volume levels, Prolaris, Vectra DA, and GeneSight would drive > $300M in incremental revenue and > $2.00 per share in incremental earnings power
Slide 27: Advancing Key Tests Toward Market Adoption
Advancing Key Tests Toward Market Adoption Total Addressable Market (TAM) $10B+ $10B+ $15B $5B Product Stage 1 DISCOVERY Stage 2 VALIDATION Stage 3 REIMBURSEMENT Stage 4 ADOPTION myRisk® Hereditary Cancer BRACAnalysis CDx™ (Tumor) EndoPredict® myChoice™ HRD myPlan® Lung Cancer myRisk® Hereditary Can